ライフサイエンスコーパス: metaiodobenzylguanidine

1 Existing tracers such as (123)I-metaiodobenzylguanidine ((123)I-MIBG) and (11)C-(-)-meta

2 -(18)F-fluorodopamine ((18)F-DA) with (123)I-metaiodobenzylguanidine ((123)I-MIBG) and somatostatin r

3 on the in vivo myocardial kinetics of (123)I-metaiodobenzylguanidine ((123)I-MIBG) are scarce and hav

4 Scintigraphic imaging with (123)I-metaiodobenzylguanidine ((123)I-MIBG) has demonstrated e

5 Cardiac (123)I-metaiodobenzylguanidine ((123)I-mIBG) imaging improves p

6 lished the prognostic significance of (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging in heart f

7 (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging is a tool

8 ympathetic nerves can be evaluated by (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging.

9 ional 2-dimensional planar imaging of (123)I-metaiodobenzylguanidine ((123)I-mIBG) is not fully quant

10 I-MIBG; through November 1999) or iodine-123-metaiodobenzylguanidine ((123)I-MIBG) scan, urine catech

11 FDOPA PET were compared with those of (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and (

12 to compare the diagnostic utility of (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and (

13 Radioiodinated metaiodobenzylguanidine ((123)I-mIBG) scintigraphy is an

14 (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy plays

15 A semiquantitative (123)I-metaiodobenzylguanidine ((123)I-MIBG) scoring method (th

16 e heart-to-mediastinum ratio (HMR) of (123)I-metaiodobenzylguanidine ((123)I-MIBG) uptake obtained us

17 uptake of (11)C-hydroxyephedrine and (123)I-metaiodobenzylguanidine ((123)I-MIBG) was examined by PE

18 he radiolabeled norepinephrine analog (123)I-metaiodobenzylguanidine ((123)I-MIBG).

19 adrenergic nerve activity assessed by (123)I-metaiodobenzylguanidine ((123)I-MIBG).

20 ths included computed tomography, iodine-131-metaiodobenzylguanidine (131)I-MIBG; through November 19

21 f the targeted radiotherapeutic agent (131)I-metaiodobenzylguanidine ((131)I-MIBG) and tested the com

22 Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) has been shown to

23 Targeted radiotherapy using (131)I-metaiodobenzylguanidine ((131)I-MIBG) has produced remis

24 Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) provides targeted

25 Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) selectively target

26 Reported experience with systemic (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy of neuroen

27 f external-beam gamma-irradiation and (131)I-metaiodobenzylguanidine ((131)I-MIBG), a radiopharmaceut

28 High-dose administration of 131I-metaiodobenzylguanidine (131I-MIBG) continues to be a pr

29 py on response and toxicity after iodine-131-metaiodobenzylguanidine (131I-MIBG) treatment of patient

30 uctions of serial autoradiographs of [(125)I]metaiodobenzylguanidine and (99m)Tc-sestamibi.

31 ase studies included imaging with 131-iodine-metaiodobenzylguanidine and extensive bone marrow (BM) s

32 iously shown that ex vivo counting of (131)I-metaiodobenzylguanidine can identify regional reductions

33 Iodine-123 metaiodobenzylguanidine (I-123 MIBG) and fluorescent mic

34 y for uptake of the radiopharmaceutical 131I-metaiodobenzylguanidine (MIBG) (3).

35 oblastoma by correlating administered (131)I-metaiodobenzylguanidine (MIBG) activity to tumor and who

36 (3-(18)F-fluoro-propoxy)benzyl)guanidine), a metaiodobenzylguanidine (MIBG) analog, for the detection

37 (123)I-metaiodobenzylguanidine (MIBG) and (111)In-pentetrotide

38 (131)I-Metaiodobenzylguanidine (MIBG) and (90)Y-DOTA-D-Phe1-Tyr

39 athetic innervation and perfusion with [123I]metaiodobenzylguanidine (MIBG) and 201Tl, respectively.

40 ter animals were injected with 37 MBq (125)I-metaiodobenzylguanidine (MIBG) followed in 3 h with 1,11

41 mpathetic denervation assessed by 123-iodine metaiodobenzylguanidine (MIBG) imaging occurs early in d

42 Radiolabeled metaiodobenzylguanidine (mIBG) is a highly sensitive and

43 (131)I-metaiodobenzylguanidine (MIBG) is specifically taken up

44 tional imaging modalities for neuroblastoma: metaiodobenzylguanidine (MIBG) scan for uptake by the no

45 ease status requires CT (or MRI), bone scan, metaiodobenzylguanidine (MIBG) scan, bone marrow tests,

46 ation that included iodine-123 or iodine-131 metaiodobenzylguanidine (MIBG) scan, bone scan, computed

47 lid Tumors (RECIST) and iodine-123 ((123)I) -metaiodobenzylguanidine (MIBG) scans or [(18)F]fluorodeo

48 clear imaging techniques such as bone scans, metaiodobenzylguanidine (MIBG) scans, and (111)In-diethy

49 (INRC) recommend, but do not make mandatory, metaiodobenzylguanidine (MIBG) scans.

50 ients with disease evaluable only by [(123)I]metaiodobenzylguanidine (MIBG) scintigraphy and/or bone

51 The high sensitivity of metaiodobenzylguanidine (MIBG) scintigraphy for sympatho

52 cells accumulated (123)I- or (124)I-labeled metaiodobenzylguanidine (MIBG) to high levels compared w

53 Metaiodobenzylguanidine (MIBG) was developed 18 yr ago f

54 Wistar rats: (201)Tl-chloride (TlCl), (123)I-metaiodobenzylguanidine (MIBG), (99m)Tc-sestamibi (MIBI)

55 ), iodine-123- (123I) and iodine-131 (131I) -metaiodobenzylguanidine (MIBG), 111In-pentetreotide, and

56 ely used theranostic agents targeting NET is metaiodobenzylguanidine (MIBG), a guanethidine analog of

57 diopharmaceuticals such as (18)F-FDG, (123)I-metaiodobenzylguanidine (MIBG), and (99m)Tc-tetrofosmin

58 Metaiodobenzylguanidine (MIBG), specifically taken up in

59 The analogue 131I-metaiodobenzylguanidine (MIBG), which is specifically ta

60 acity to accumulate the noradrenaline analog metaiodobenzylguanidine (MIBG).

61 approved clinical grade radiolabeled probe, metaiodobenzylguanidine (MIBG).

62 important advances have occurred using 131I metaiodobenzylguanidine (MIBG).

63 Magnetic resonance imaging, metaiodobenzylguanidine scan, single-photon emission tom

64 eochromocytomas are best diagnosed with 131I-metaiodobenzylguanidine scanning.

65 Postinduction metaiodobenzylguanidine scans showed normal radiotracer

66 Nuclear imaging approaches, such as(123) I-metaiodobenzylguanidine scintigraphy and 6-[(18) F]fluor

67 Cardiac (123)I-metaiodobenzylguanidine scintigraphy was conducted in a

68 atients evaluable for response by iodine-123 metaiodobenzylguanidine score had objective responses (f

69 cted in PD with (18)F-dopamine PET or (123)I-metaiodobenzylguanidine SPECT.

70 rine, (11)C-metahydroxyephedrine, and (123)I-metaiodobenzylguanidine that measure cardiac sympathetic

71 xtravasation of a therapeutic dose of (131)I-metaiodobenzylguanidine that produced a radiation burn t